A medical journal has retracted a paper detailing the main study for Amgen's drug Tavneos following findings from the FDA. The retraction comes after scrutiny of the trial data.

Amgen has engaged a Duke research organization in an effort to prevent its drug Tavneos from being removed from the market.

The U.S. Food and Drug Administration (FDA) has confirmed that Amgen's drug Tavneos is linked to cases of liver injuries and deaths, as reported by the Wall Street Journal.

An EU regulatory committee has recommended the revocation of marketing authorization for Tavneos, a drug for the rare disease vasculitis, following reports of patient deaths and concerns that its benefits do not outweigh the risks; a Japanese pharmaceutical company is discussing the situation with its government.

Kissei has been ordered to add a warning to its vasculitis drug, Tavneos, after 20 patients died from liver dysfunction following its use.

Amgen is confronting the withdrawal of its rare disorder therapy, Tavneos, from the U.S. market, posing challenges for patients and the company.

The U.S. Food and Drug Administration (FDA) has stated that Amgen's drug Tavneos has been linked to cases of liver injuries and deaths, as reported by the Wall Street Journal.

Switzerland is closely monitoring concerns raised by Japan regarding the drug Tavneos.

The FDA has announced that Amgen's drug Tavneos has been linked to instances of liver injuries and fatalities.

The FDA has issued a warning regarding Amgen's drug Tavneos following reports of serious liver injury cases associated with its use.